Drug reference

Streptozocin

Alkylating Agent · Antineoplastic

Also known as Streptozotocin

Alkylating AgentAntineoplastic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

Avoid

FDA category + note

Top interactionssee all 12 →

Other Nephrotoxic DrugsSevereTextbookG&G 14e · p1351
AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter

Mechanism

Streptozocin is a nitrosourea alkylating agent. It causes selective damage to insulin-secreting beta cells of the pancreas, which contributes to its therapeutic effect in certain pancreatic neuroendocrine tumors.

Indications

Neuroendocrine tumours of pancreatic origin (specialist use only)Malignant pancreatic insulinomaMalignant carcinoidhuman pancreatic islet cell carcinomacarcinoid tumors

Dosing

Adult: (consult product literature)
Renal adjustment: Avoid in severe impairment

Pharmacokinetics

Onset

not specified

Peak effect

not specified

Protein binding

not specified

Metabolism

not specified

Contraindications

Pregnancy
Severe renal impairment

Side effects

Common

Acute kidney injuryDiarrhoeaNauseaNephropathyRenal tubular injuryUrinary disorderUrine abnormalitiesVomitingnausea (frequent)renal toxicity (mild, reversible in approximately two-thirds of cases)hepatic toxicity (mild, reversible in approximately two-thirds of cases)anemia (in 20% of patients)leukopenia (in 20% of patients)thrombocytopenia (in 20% of patients)

Serious

Confusion
Depression
Extravasation necrosis
Fever
Glucose tolerance impaired
Hepatotoxicity
Hypoalbuminaemia
Lethargy
renal toxicity (may be cumulative with each dose and lead to irreversible renal failure in fewer than 10% of patients)